Literature DB >> 12573105

Genetic engineering of streptavidin-binding peptide tagged single-chain variable fragment antibody to Venezuelan equine encephalitis virus.

Wei-Gang Hu1, Azhar Z Alvi, R Elaine Fulton, Mavanur R Suresh, Les P Nagata.   

Abstract

A recombinant gene encoding a single-chain variable fragment (scFv) antibody against Venezuelan equine encephalitis virus (VEE) was cloned into a prokaryotic T7 RNA polymerase-regulated expression vector. A streptavidin-binding peptide gene fused to a 6His tag was attached downstream to the scFv gene. The recombinant fusion protein was expressed in bacteria as inclusion bodies that were subsequently solubilized with 8 M urea and renatured by an arginine system. Purification of the fusion protein was achieved by immobilized metal affinity chromatography. Enzyme-linked immunosorbent assay (ELISA) and Western blotting results revealed that the fusion protein not only retained VEE antigen binding and specificity properties similar to those of its parent native monoclonal antibody (MAb), but also possessed streptavidin-binding activity. This experimental approach can eliminate the need for chemical biotinylation of antibodies and the risk associated of antibody denaturation and can provide a stable and reproducible reagent for rapid and efficient immunoassay of VEE when detected by horseradish peroxidase (HRP)-conjugated streptavidin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12573105     DOI: 10.1089/153685902321043945

Source DB:  PubMed          Journal:  Hybrid Hybridomics        ISSN: 1536-8599


  1 in total

1.  Isolation and characterisation of a human-like antibody fragment (scFv) that inactivates VEEV in vitro and in vivo.

Authors:  Torsten Rülker; Luzie Voß; Philippe Thullier; Lyn M O' Brien; Thibaut Pelat; Stuart D Perkins; Claudia Langermann; Thomas Schirrmann; Stefan Dübel; Hans-Jürgen Marschall; Michael Hust; Birgit Hülseweh
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.